Drug Trial Radar · NCT07078955
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
99
Planned (sponsor's estimate)
Start
Dec 2025
Primary completion
Nov 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- BRIM Biotechnology Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
Conditions
- Dry Eye Disease (DED)
- Keratoconjunctivitis Sicca
Interventions
BRM421 Ophthalmic Solution, 0.03%Drug
A topical drop of 0.03% BRM421 ophthalmic solution.
Artificial TearDrug
A topical drop of Artificial Tear.
BRM421 Ophthalmic Solution, 0.06%Drug
A topical drop of 0.06% BRM421 ophthalmic solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in total corneal fluorescein staining (tCFS) scoreTime frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Taipei Municipal TuCheng Hospital
New Taipei City, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.